| Literature DB >> 32083219 |
Meghan Mayhew1, Michael C Leo1, William M Vollmer1, Lynn L DeBar2, Michaela Kiernan3.
Abstract
BACKGROUND: Intervention adherence and trial retention are challenging for clinical trials testing intensive behavioral interventions. Operational constraints or trial designs may preclude using effective retention strategies such as financial incentives. We examined whether implementing pre-enrollment orientation sessions was associated with higher intervention adherence and retention in a pragmatic clinical trial.Entities:
Keywords: Adherence; Behavioral intervention; Orientation session; Patient recruitment; Pragmatic clinical trial; Retention
Year: 2020 PMID: 32083219 PMCID: PMC7025079 DOI: 10.1016/j.conctc.2020.100527
Source DB: PubMed Journal: Contemp Clin Trials Commun ISSN: 2451-8654
Fig. 1PPACT recruitment and study activities at KPNW site.
Fig. 2Pros and cons of participating in a research study.
Fig. 3Intervention groups attended pre- & post-implementation of orientation sessions.
Unadjusted retention rates before and after implementing orientation sessions by PPACT trial arm.
| Before Implementing Orientation Sessions | After Implementing Orientation Sessions | ||||||
|---|---|---|---|---|---|---|---|
| Time Point | Intervention (N = 104) | Usual Care (N = 105) | Total (N = 209) | Intervention (N = 138) | Usual Care (N = 120) | Total (N = 258) | Difference After-Before |
| 3-month | 87.5% | 90.5% | 89.0% | 95.7% | 95.0% | 95.4% | 6.4% |
| 6-month | 88.5% | 84.8% | 86.6% | 93.5% | 90.8% | 92.3% | 5.7% |
| 9-month | 86.5% | 84.8% | 85.7% | 87.7% | 90.0% | 88.8% | 3.1% |
| 12-month | 88.5% | 83.8% | 86.1% | 89.1% | 87.5% | 88.4% | 2.3% |
Characteristics of KPNW PPACT trial participants before and after implementing orientation sessions.
| Before Implementation | After Implementation | |||||
|---|---|---|---|---|---|---|
| N (%) or Mean, (SD) | Enrolled in Trial | Potentially Eligible | Difference (Enrolled-Eligible) | Enrolled in Trial | Potentially Eligible | Difference (Enrolled-Eligible) |
| Age, yrs. | 58.3 (12.2) | 57.2 (13.1) | 1.1 | 62.0 (12.0) | 58.8 (13.7) | 3.2 |
| Female | 153 (73.2%) | 1492 (65.5%) | 7.7% | 180 (69.8%) | 2247 (59.6%) | 10.2% |
| Race | ||||||
| White | 192 (91.9%) | 2081 (91.4%) | 0.5% | 244 (94.6%) | 3312 (87.8%) | 6.8% |
| Black or African American and Other | 17 (8.1%) | 196 (8.6%) | −0.5% | 14 (5.4%) | 461 (12.2%) | −6.8% |
| Hispanic ethnicity | 7 (3.4%) | 64 (2.8%) | 0.6% | 3 (1.2%) | 124 (3.3%) | −2.1% |
| Substance use | ||||||
| Current smoking | 48 (23.0%) | 582 (25.6%) | −2.6% | 40 (15.5%) | 742 (19.7%) | −4.2% |
| Alcohol abuse | 10 (4.8%) | 58 (2.6%) | 2.2% | 12 (4.7%) | 106 (2.8%) | 1.9% |
| Drug abuse | 11 (5.3%) | 74 (3.3%) | 2.0% | 7 (2.7%) | 116 (3.1%) | −0.4% |
| Chronic medical conditions | ||||||
| Diabetes | 51 (24.4%) | 478 (21.0%) | 3.4% | 62 (24.0%) | 773 (20.5%) | 3.5% |
| Cardiovascular disorder | 52 (24.9%) | 388 (17.0%) | 7.9% | 58 (22.5%) | 734 (19.5%) | 3.0% |
| Hypertension | 90 (43.1%) | 847 (37.2%) | 5.9% | 97 (37.6%) | 1207 (32.0%) | 5.6% |
| Chronic pulmonary disease | 48 (23.0%) | 413 (18.1%) | 4.9% | 48 (18.6%) | 668 (17.7%) | 0.9% |
| Two or more of above chronic medical conditions | 67 (32.1%) | 595 (26.1%) | 6.0% | 78 (30.2%) | 950 (25.2%) | 5.0% |
| Mental health comorbidities | ||||||
| Anxiety | 49 (23.4%) | 377 (16.6%) | 6.8% | 52 (20.2%) | 668 (17.7%) | 2.5% |
| Depression | 90 (43.1%) | 693 (30.4%) | 12.7% | 99 (38.4%) | 920 (24.4%) | 14.0% |
| Other mental health diagnoses | 16 (7.7%) | 63 (2.8%) | 4.9% | 15 (5.8%) | 92 (2.4%) | 3.4% |
| Chronic pain-related clinical characteristics | ||||||
| Number of non-malignant chronic pain types, mean (SD) | 3.2 (1.7) | 2.5 (1.7) | 0.7 | 2.6 (1.7) | 2.3 (1.7) | 0.3 |
| Average daily morphine milligram equivalent (MME) dose ≥90 | 55 (26.3%) | 468 (20.6%) | 5.7% | 36 (14.0%) | 394 (10.4%) | 3.6% |
| Benzodiazepine receipt | 57 (27.3%) | 623 (27.4%) | −0.1% | 66 (25.6%) | 839 (22.2%) | 3.4% |
| High utilizer of primary care services | 12 (5.7%) | 81 (3.6%) | 2.1% | 10 (3.9%) | 126 (3.3%) | 0.6% |